Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors
preprint
OA: closed
AI-generated summary
Computational design efforts yielded two novel dipeptidyl peptidase-4 inhibitors with improved docking scores compared to anagliptin.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ABSTRACT The Type 2 Diabetes Mellitus (T2DM) epidemic undoubtedly creates a need for the development of new pharmaceuticals. With the goal of generating new therapeutics for this disease, computational studies were conducted to design novel dipeptidyl peptidase-4 (DPP-4) inhibitors. Two candidates, generated by chemical intuition-driven design and bioisosteric replacement, were found to have better docking scores than anagliptin, a currently available diabetes medication.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00